Endocrine Reviews Journal Article

Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond

July 19, 2019

Maria E Cabanillas, Mabel Ryder, Camilo Jimenez
Endocrine Reviews, Volume 40, Issue 6, December 2019, Pages 1573–1604
https://doi.org/10.1210/er.2019-00007

Abstract

The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade, with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a number of other commercially available drugs that have been studied for this indication. Although most of the US Food and Drug Administration (FDA)–approved drugs are antiangiogenic multikinase inhibitors—vandetanib, cabozantinib, sorafenib, lenvatinib—there are two FDA indications that are mutation specific—dabrafenib/trametinib for BRAF-mutated anaplastic thyroid cancer and larotrectinib for NTRK-fusion thyroid cancer. Furthermore, other mutation-specific drugs, immunotherapies, and novel strategies for advanced thyroid cancer are under investigation. Understanding the molecular basis of thyroid cancer, the drugs of interest for treatment of advanced thyroid cancer, and how these drugs can be administered safely and in the appropriate clinical scenario are the topics of this review.

Read the article


You may also like...

JCEM

New Year, New Look

JCEM
JCEM, the most-cited journal in Endocrinology & Metabolism, has a new look for 2020. Check out the latest published articles and sign-up for advanced article alerts today.

Same Great Science

JCEM, the most-cited journal in Endocrinology & Metabolism, has a new look for 2020. Check out the latest published articles and sign-up for advanced article alerts today.

Thematic Issue

Immuno-endocrinology 2020

immuno-endocrinology
Read our special collection of journal articles, published in 2018-2019, focused on immuno-endocrinology! Curation of the collection was guided by Altmetric Attention Scores and Featured Article designations.

Read our special collection of journal articles, published in 2018-2019, focused on immuno-endocrinology! Curation of the collection was guided by Altmetric Attention Scores and Featured Article designations.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!